Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab : immortal time bias-corrected analysis
© 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology..
BACKGROUND: Immune-related adverse events (irAEs) in patients treated with immune check inhibitors are associated with favourable response rate and survivals in multiple cancers, including renal cell carcinoma (RCC). The aim of this study was to investigate how irAEs were associated with improved survivals in advanced RCC patients treated with nivolumab plus ipilimumab.
MATERIALS AND METHODS: This retrospective study included patients who received nivolumab plus ipilimumab at six centres, institutions, or hospitals between September 2018 and February 2022. We assessed associations of the development and the number of irAEs with overall survival (OS) and progression-free survival (PFS). To eliminate immortal time bias, landmark analysis and a Cox model with time-dependent variables were used.
RESULTS: This study included 129 patients with a median follow-up of 12.3 months. The 2-year OS and PFS rates were 55% and 42%, respectively. Ninety six patients experienced irAEs. The development of irAEs was positively associated with OS and PFS rates (hazard ratio [HR] 0.328, 95% confidence interval [CI] 0.165-0.648, p = 0.001; HR 0.334, 95% CI 0.151-0.737, p = 0.007). Patients who experienced multiple irAEs had longer OS (HR 0.507, 95% CI 0.235-1.097, p = 0.085 or HR 0.245, 95% CI 0.110-0.544, p < 0.001) and PFS (HR 0.572, 95% CI 0.316-1.036, p = 0.085 or HR 0.267, 95% CI 0.113-0.628, p = 0.002) compared with those who experienced single or zero irAE.
CONCLUSIONS: Developing irAEs, particularly multiple irAEs, is associated with favourable survivals in advanced RCC patients treated with nivolumab plus ipilimumab.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
International journal of clinical oncology - 28(2023), 12 vom: 02. Dez., Seite 1651-1658 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Washino, Satoshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
31YO63LBSN |
|---|
| Anmerkungen: |
Date Completed 01.12.2023 Date Revised 01.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10147-023-02406-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36156662X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36156662X | ||
| 003 | DE-627 | ||
| 005 | 20231226085420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10147-023-02406-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1205.xml |
| 035 | |a (DE-627)NLM36156662X | ||
| 035 | |a (NLM)37658926 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Washino, Satoshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab |b immortal time bias-corrected analysis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.12.2023 | ||
| 500 | |a Date Revised 01.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s) under exclusive licence to Japan Society of Clinical Oncology. | ||
| 520 | |a BACKGROUND: Immune-related adverse events (irAEs) in patients treated with immune check inhibitors are associated with favourable response rate and survivals in multiple cancers, including renal cell carcinoma (RCC). The aim of this study was to investigate how irAEs were associated with improved survivals in advanced RCC patients treated with nivolumab plus ipilimumab | ||
| 520 | |a MATERIALS AND METHODS: This retrospective study included patients who received nivolumab plus ipilimumab at six centres, institutions, or hospitals between September 2018 and February 2022. We assessed associations of the development and the number of irAEs with overall survival (OS) and progression-free survival (PFS). To eliminate immortal time bias, landmark analysis and a Cox model with time-dependent variables were used | ||
| 520 | |a RESULTS: This study included 129 patients with a median follow-up of 12.3 months. The 2-year OS and PFS rates were 55% and 42%, respectively. Ninety six patients experienced irAEs. The development of irAEs was positively associated with OS and PFS rates (hazard ratio [HR] 0.328, 95% confidence interval [CI] 0.165-0.648, p = 0.001; HR 0.334, 95% CI 0.151-0.737, p = 0.007). Patients who experienced multiple irAEs had longer OS (HR 0.507, 95% CI 0.235-1.097, p = 0.085 or HR 0.245, 95% CI 0.110-0.544, p < 0.001) and PFS (HR 0.572, 95% CI 0.316-1.036, p = 0.085 or HR 0.267, 95% CI 0.113-0.628, p = 0.002) compared with those who experienced single or zero irAE | ||
| 520 | |a CONCLUSIONS: Developing irAEs, particularly multiple irAEs, is associated with favourable survivals in advanced RCC patients treated with nivolumab plus ipilimumab | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Immune-related adverse events | |
| 650 | 4 | |a Ipilimumab | |
| 650 | 4 | |a Nivolumab | |
| 650 | 4 | |a Renal cell carcinoma | |
| 650 | 4 | |a Survival | |
| 650 | 7 | |a Nivolumab |2 NLM | |
| 650 | 7 | |a 31YO63LBSN |2 NLM | |
| 650 | 7 | |a Ipilimumab |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents, Immunological |2 NLM | |
| 700 | 1 | |a Shirotake, Suguru |e verfasserin |4 aut | |
| 700 | 1 | |a Takeshita, Hideki |e verfasserin |4 aut | |
| 700 | 1 | |a Inoue, Masaharu |e verfasserin |4 aut | |
| 700 | 1 | |a Miura, Yuji |e verfasserin |4 aut | |
| 700 | 1 | |a Hyodo, Yoji |e verfasserin |4 aut | |
| 700 | 1 | |a Kagawa, Makoto |e verfasserin |4 aut | |
| 700 | 1 | |a Izumi, Keita |e verfasserin |4 aut | |
| 700 | 1 | |a Oyama, Masafumi |e verfasserin |4 aut | |
| 700 | 1 | |a Kawakami, Satoru |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Kazutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Matsuoka, Yoh |e verfasserin |4 aut | |
| 700 | 1 | |a Taniuchi, Satsuki |e verfasserin |4 aut | |
| 700 | 1 | |a Shintani, Ayumi |e verfasserin |4 aut | |
| 700 | 1 | |a Miyagawa, Tomoaki |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of clinical oncology |d 1997 |g 28(2023), 12 vom: 02. Dez., Seite 1651-1658 |w (DE-627)NLM095566163 |x 1437-7772 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:12 |g day:02 |g month:12 |g pages:1651-1658 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10147-023-02406-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 12 |b 02 |c 12 |h 1651-1658 | ||